Mangoceuticals, Inc. Comprehensive Income
Mangoceuticals, Inc. (MGRX) reported Comprehensive Income of -$1.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Mangoceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$1.32M.
- Mangoceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$3.40M.
- Mangoceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$2.77M.
- Mangoceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$7.62M.
- Mangoceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$20.64M.
- Mangoceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$8.72M.
- Mangoceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$9.21M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.32M 10-Q · filed 2026-08-13 | -$4.72M 10-Q · filed 2026-08-13 | -$7.49M derived: sum of 3 quarters · filed 2026-08-13 | -$15.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$3.40M 10-Q · filed 2026-05-19 | -$6.17M derived: sum of 2 quarters · filed 2026-05-19 | -$13.79M derived: sum of 3 quarters · filed 2026-05-19 | -$19.21M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$10.39M derived: sum of 2 quarters · filed 2026-04-01 | -$15.80M derived: sum of 3 quarters · filed 2026-08-13 | -$20.64M 10-K · filed 2026-04-01 |
| 2025-09-30 | -$7.62M 10-Q · filed 2025-11-14 | -$13.03M derived: sum of 2 quarters · filed 2026-08-13 | -$17.88M 10-Q · filed 2025-11-14 | -$19.82M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$5.42M 10-Q · filed 2026-08-13 | -$10.25M 10-Q · filed 2026-08-13 | -$12.20M derived: sum of 3 quarters · filed 2026-08-13 | -$14.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$4.83M 10-Q · filed 2026-05-19 | -$6.79M derived: sum of 2 quarters · filed 2026-05-19 | -$8.79M derived: sum of 3 quarters · filed 2026-05-19 | -$11.18M derived: sum of 4 quarters · filed 2026-05-19 |
| 2024-12-31 | -$1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$3.96M derived: sum of 2 quarters · filed 2026-04-01 | -$6.35M derived: sum of 3 quarters · filed 2026-04-01 | -$8.72M 10-K · filed 2026-04-01 |
| 2024-09-30 | -$2.00M 10-Q · filed 2025-11-14 | -$4.39M derived: sum of 2 quarters · filed 2025-11-14 | -$6.76M 10-Q · filed 2025-11-14 | -$9.33M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$2.39M 10-Q/A · filed 2025-11-14 | -$4.76M 10-Q/A · filed 2025-11-14 | -$7.33M derived: sum of 3 quarters · filed 2025-11-14 | -$9.13M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-03-31 | -$2.37M 10-Q · filed 2025-05-15 | -$4.94M derived: sum of 2 quarters · filed 2025-05-15 | -$6.74M derived: sum of 3 quarters · filed 2025-05-15 | -$9.02M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$4.37M derived: sum of 2 quarters · filed 2025-03-20 | -$6.65M derived: sum of 3 quarters · filed 2025-03-20 | -$9.21M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$1.80M 10-Q · filed 2024-11-14 | -$4.08M derived: sum of 2 quarters · filed 2024-11-14 | -$6.64M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$2.28M 10-Q · filed 2024-08-14 | -$4.84M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$2.56M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |